fda warning letters compounded tirzepatide 2024 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of US FDA sends 25 letters
Description
doi: 10.1016/j.cjca.2020.02.066 115 HoritaSSekiGYamadaHSuzukiMKoikeKFujitaT
We monitor your lipase levels and renal function through regular blood work to ensure your treatment remains safe and effective for your specific physiology
Plaintiffs had their chance to give FDA relevant information
Existing gastrointestinal issues, medication interactions, endocrine disorders, pregnancy considerations, and prior treatment response all need to be reviewed carefully
It is not uncommon for patients using tirzepatide for weight loss to lose 10 to 15% or more of their starting body weight over a year of usage
